Inebilizumab
Monoclonal antibody
Evidence outlook
Approved: Generalized Myasthenia Gravis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Systemic Lupus Erythematosus · Phase 2
Also approved (7)
- adult patients with immunoglobulin G4-Related Disease (IgG4-RD)
- UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
- add-on to standard therapy for adults with generalised myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive
- adults with active immunoglobulin G4-related disease (IgG4-RD)
- Monotherapy for adults with AQP4-IgG seropositive neuromyelitis optica spectrum disorders (Uplizna)
- AQP4-antibody positive NMOSD in adults (Xinyue, Hansoh)
- Prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
MINT NCT04524273 · Myasthenia Gravis Participants were randomly assigned and everyone involved (participants, care providers, investigators and outcome assessors) was masked, with a placebo comparator and 238 participants. The primary endpoint, change in the MG-ADL symptom and function score at Week 26, is a validated clinical measure and was met (p<0.0001). Registry: NCT04524273 | 3 | Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population (Baseline and Week 26) 2024-05-28 | Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population (Baseline and Week 26): Overall: Placebo -2.2 Score on a scale (95% CI -3 to -1.5) | Overall: Inebilizumab 300 mg -4.2 Score on a scale (95% CI -4.9 to -3.4) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other CD19 drugs
obecabtagene autoleucel, Tafasitamab, budoprutug, cemacabtagene ansegedleucel, FT819 and 11 more. Compare all 17 CD19 drugs
This mechanism is crowded: 18 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Generalized Myasthenia Gravis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Inebilizumab: this drug | Approved | Monoclonal antibody | CD19 | Reliable signal | NCT04524273: Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population (Baseline and Week 26): Overall: Placebo -2.2 Score on a scale (95% CI -3 to -1.5) | Overall: Inebilizumab 300 mg -4.2 Score on a scale (95% CI -4.9 to -3.4) | |
| Eculizumab (Soliris) | Approved | Monoclonal antibody | Complement C5 | Partial signal | NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed | |
| Efgartigimod Alfa (Vyvgart) | Approved | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo) | Approved | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Obecabtagene Autoleucel (Aucatzyl) | Approved(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved(overall) | Monoclonal antibody | CD19 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Cemdisiran | Phase 3 | RNA / oligonucleotide | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Gefurulimab (Klygefa) | Phase 3 | Antibody-derived scaffold | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Iptacopan (Fabhalta) | Phase 3 | Small molecule | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Pozelimab (Veopoz) | Phase 3 | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Telitacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Cemacabtagene Ansegedleucel | Phase 2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Rapcabtagene Autoleucel | Phase 2(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aritinercept | Phase 1/2 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Azercabtagene Zapreleucel | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-619 | —(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| GLPG5101 | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(12 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Inebilizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
April 2027 (1)
What to watch
August 2027 (1)
What to watch
2028 (4)
2029 (1)
February 2029 (1)
What to watch
2030 (2)
2031 (3)
June 2031 (1)
What to watch
July 2031 (1)
What to watch
September 2031 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent